Japan To Speed Approval Process For Academically Developed Drugs
This article was originally published in PharmAsia News
Academically developed drugs are to get faster reviews in Japan under a regulatory change to become effective as early as fiscal 2014.
You may also be interested in...
Despite the urgency to have many more notified bodies designated under the MDR and IVDR, COVID-19 fall-out has resulted in a hiatus in their appointment, Commission figures show.
Reckitt hires chief digital officer from Nestlé and shakes up Australia leadership; GSCF names Bayer's Schipper as chair; and Europe's CMDh appoints a new chair.
During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.